Advertisement

Topics

Solasia Pharma K.K. and Camurus AB Company Profile

20:53 EST 21st January 2019 | BioPortfolio

Solasia was formed in November 2006 by MPM Capital and ITOCHU Corporation to address unmet needs for important new Western oncology therapies and supportive care products throughout Asia. The company’s mission is to expedite patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries.


News Articles [429 Associated News Articles listed on BioPortfolio]

Solasia Initiates Phase III Program for PledOx in Japan

Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President CEO: Yoshihiro Arai, hereinafter "Solasia") announced the initiation of Phase III clinical trial for PledOx in Japan. In Nove...

Camurus AB: US FDA Issues A Tentative Approval of Brixadi™ (buprenorphine) Extended-release ...

LUND, Sweden, Dec. 23, 2018 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) announced today that the US Food and Drug Administration (FDA) has issued Camurus' US Read more...

Camurus AB: US FDA Issues A Tentative Approval of Brixadi (buprenorphine) Extended-release Injection for Treatment of Opioid Use Disorder

LUND, Sweden, Dec. 23, 2018 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) announced today that the US Food and Drug Administration (FDA) has issued Camurus' US partner Braeburn a tentative approval o...

Camurus, Braeburn's opioid use disorder drug nabs tentative FDA nod

Camurus and Braeburn's Brixadi, or buprenorphine, extended-release injection for weekly and monthly subcutaneous use in patie -More- 

EU approves Camurus’s Buvidal injections to treat opoid dependency

Swedish research-based pharmaceutical and biotechnology company Camurus has received European Commission (EC) approval for weekly and monthly Buvidal injections to...Read More... The post EU approves ...

EC OKs Camurus' weekly, monthly opioid dependence drug

The European Commission has approved Camurus' weekly and monthly Buvidal, or prolonged release buprenorphine, as a treatment  -More- 

Camurus Receives EU Approval for Weekly and Monthly Buvidal (CAM2038) for Opioid Dependence

- Buvidal is the first long-acting medicine approved in the EU for the treatment of opioid dependence in adults and adolescents LUND, Sweden, Nov. 22, 2018 /PRNewswire/ -- Camurus announced today ...

Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder

LUND, Sweden, 16 July, 2018 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) announced today that the US Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) goal date of...

Drugs and Medications [61 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [Mayne Pharma Inc]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Mayne Pharma Inc]

Fluoride Chewable Tablets 1 mg

Urea [Mayne Pharma Inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [Aventis Pharma Ltd.]

NA

Ribavirin [Aurobindo Pharma Limited]

NA

PubMed Articles [24 Associated PubMed Articles listed on BioPortfolio]

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Clinical trials go virtual, big pharma dives in.

Disease awareness advertising (DAA) in emerging economy: A comparison between views of consumers and pharmaceutical professionals.

Research on effectiveness of DAA is limited. Existing researches explore impact of DAA only on relationship between drug manufacturers and consumers. However, in reality, pharma marketing revolves aro...

21 Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ...

CVS and the $100,000 QALY.

The PBM unit of the health giant CVS decided that any new drug exceeding $100,000 per quality-adjusted life year (QALY) may be excluded from the formularies that are maintained by its clients. Patient...

Clinical Trials [85 Associated Clinical Trials listed on BioPortfolio]

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (L...

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection of...

Companies [788 Associated Companies listed on BioPortfolio]

Solasia Pharma K.K. and Camurus AB

Solasia was formed in November 2006 by MPM Capital and ITOCHU Corporation to address unmet needs for important new Western oncology therapies and supportive care products througho...

Solasia Pharma K.K.

Solasia Pharma K.K. (Tokyo, Japan) was formed in November 2006 by MPM Capital and Itochu Corporation to address unmet needs for important new Western oncology therapies throughout...

Camurus AB

Camurus is a drug delivery company, within the healthcare sector, that specializes in formulation technologies of sparingly water soluble drug substances. Camurus offer proprietary technology platform...

H3 Pharma Incorporated

H3 Pharma Inc. is a Venture Pharma focusing on the development of human therapeutic products oriented towards age-related disorders. At H3 Pharma, we aim to be the best at identifying, evaluating and ...

LEO Pharma Inc.

LEO Pharma Inc. is headquartered in Parsippany, New Jersey, and is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology and critical care with more t...

More Information about "Solasia Pharma K.K. and Camurus AB" on BioPortfolio

We have published hundreds of Solasia Pharma K.K. and Camurus AB news stories on BioPortfolio along with dozens of Solasia Pharma K.K. and Camurus AB Clinical Trials and PubMed Articles about Solasia Pharma K.K. and Camurus AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Solasia Pharma K.K. and Camurus AB Companies in our database. You can also find out about relevant Solasia Pharma K.K. and Camurus AB Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record